Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the EDGAR system. As a Nasdaq‑listed biopharmaceutical issuer incorporated in England and Wales, Kiniksa uses these filings to report financial results, clinical and regulatory milestones, and other material corporate information.
Form 8‑K filings for KNSA document events such as quarterly financial results, investor presentations, and other significant updates. For example, Kiniksa has used Form 8‑K to furnish press releases announcing results for quarters ended June 30 and September 30, 2025, and to file an investor presentation used in meetings with investors and analysts. These filings also confirm that Kiniksa’s Class A ordinary shares trade on The Nasdaq Global Select Market under the symbol KNSA.
Investors can also review Kiniksa’s periodic reports, such as Forms 10‑K and 10‑Q, which typically contain detailed information on ARCALYST net product revenue, operating expenses, cash, cash equivalents, and short‑term investments, as well as risk factors and discussion of the company’s IL‑1‑focused portfolio. For a biopharmaceutical company like Kiniksa, these reports are central to understanding how ARCALYST commercialization and the development of KPL‑387 and KPL‑1161 affect overall financial performance and strategy.
On Stock Titan, AI‑powered summaries help interpret lengthy KNSA filings by highlighting key points in plain language, such as changes in revenue guidance, updates on the Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, or disclosures about Orphan Drug Designation. Users can quickly locate references to IL‑1R1‑targeted programs, cardiovascular indications, and other topics without reading every page.
In addition, the filings page offers streamlined access to other important documents, including any proxy statements and beneficial ownership or insider‑related filings when available. Together, these SEC documents and AI‑generated insights give readers a structured view of Kiniksa’s regulatory history, financial reporting, and pipeline‑related disclosures.
Report: Form 4 filed for Ragosa Mark (address: 23 Old Bond Street, London) reporting transactions in Kiniksa Pharmaceuticals International, plc (KNSA). The reporting person is identified as a Director and Chief Financial Officer. Earliest transaction date: 08/04/2025. Form signed by Madelyn Zeylikman, Attorney-in-Fact, dated 08/06/2025.
Transactions: Table I shows two Class A Ordinary Share transactions on 08/04/2025 involving 18,889 shares at prices of $22.89 and $32.89, with reported post-transaction beneficial ownerships of 45,898 and 27,009. Table II reports a Share Option with exercise/conversion price $22.89 covering 18,889 underlying Class A shares, expiration 03/15/2031, and 2,036 derivative securities reported beneficially owned following the transaction. The filing states the transactions were effected pursuant to a 10b5-1 plan executed Sept 3, 2024 and discloses the option vesting schedule (vesting commencement 03/16/2021; 25% on first anniversary; monthly vesting over 36 months).
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
